U.S. Biotech Companies Outpace European Counterparts In Funding, Report Says
This article was originally published in The Pink Sheet Daily
The U.S. biotech industry received 81% of total equity and debt funding raised by biotechs in 2004 despite having fewer companies than Europe, Critical I consulting firm finds.
You may also be interested in...
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.